Q1 2025 Embla Medical hf Earnings Call Transcript
Key Points
- Embla Medical hf (OSSUY) reported a 4% organic growth in sales for Q1 2025, amounting to $203 million.
- The company achieved a 1% increase in gross profit margin, reaching 63%, driven by cost reduction initiatives and a positive product mix.
- Strong growth was observed in the prosthetics and neuro orthotics segment, with 9% organic growth, particularly in the EMEA and APAC regions.
- The company successfully launched new products, Navii and Icon bionic knees, following positive user feedback.
- Embla Medical hf (OSSUY) reinitiated its share buyback program, reflecting confidence in its financial position and capital structure.
- Sales in the Americas declined by 1% in Q1 2025, primarily due to lower sales in the patient care business area.
- The company faces uncertainties related to US trade tariffs, which could impact costs and supply chain adjustments.
- Patient care sales in the US were affected by lower patient volumes and slow reimbursement approvals.
- Sales in the bracing and support segment were flat, with challenges in the UK and a decline in China impacting overall performance.
- The company noted variability in performance across regions, with some areas experiencing softer sales growth.
At this time, I would like to welcome everyone to this Embla Medical Q1 2025 conference call.
I would now like to introduce CEO, Sveinn Solvason. Sveinn, over to you. (Operator Instructions)
Thank you very much and good morning and welcome to the Embla Medical conference call where we will review the first quarter for 2025. I'm Sveinn Solvason, President and CEO of Embla Medical , and joining me on today's call is our Chief Financial Officer Arna Sveinsdottir and Embla Medical head of investor relations klaus Sindhal.
The presentation should take approximately 15 minutes after which there will be an opportunity to ask questions during a Q&A session.
You now go to the next la please.
We are off to a reasonably good start here in 2025. Sales in the first quarter amounted to $203 million and organic growth came in at 4%.
Where we had a particularly good few weeks at the end of the quarter.
Growth was strong in our prosthetics and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
